Cardiogen
Cardiogen is a synthetic tetrapeptide (Ala-Glu-Asp-Arg, abbreviated AEDR) from the Khavinson short-peptide bioregulator program, studied as a cardiovascular-tissue signalling molecule; research protocols typically use 10 mg sublingually each morning in short 10-20 day courses. Human evidence is very thin — what exists is in vitro work and small Russian-language reports from essentially one research group.
Adults researching the Khavinson bioregulator class for cardiovascular-aging signalling. This is a research-interest compound rather than a cardiac therapy: no controlled Western trial has reported a clinical cardiac outcome for it, and it is not a substitute for cardiology care or prescribed cardiac medication.
Cardiogen is a four-amino-acid peptide, Ala-Glu-Asp-Arg, developed at the St. Petersburg Institute of Bioregulation and Gerontology by Vladimir Khavinson's group. The program's method was to fractionate animal-tissue extracts (here, cardiac tissue) down to short peptide sequences and then synthesize those sequences as defined molecules — so Cardiogen is the synthetic, single-molecule successor to a cardiac tissue extract rather than an extract itself.
The proposed mechanism in this literature is epigenetic: ultrashort peptides of this class are described as entering the cell and nucleus and binding DNA in a sequence-preferential way, modulating transcription of tissue-relevant genes. A 2022 review from the developing group positions the AEDR tetrapeptide, alongside the KED tripeptide (Vesugen), as regulating molecules involved in inflammaging and the senescence-associated secretory phenotype of cardiovascular cells. Separate molecular-modelling work from the same group proposes that these peptides could be carried across membranes by the LAT1, LAT2, and PEPT1 amino-acid and peptide transporters, which is the theoretical basis for a sublingual or oral route — it is a docking prediction, not a measured absorption study.
The evidentiary situation should be stated plainly: PubMed indexes no controlled human trial of Cardiogen. The supporting literature is preclinical, review-level, or published in Russian-language journals by the group that developed the compound, and it has not been independently replicated in the West. Nothing here establishes a clinical cardiac effect in humans, and the peptide is not approved by any regulator for any indication.
Sublingual, once daily in the morning. The catalog reference is 10 mg per day, with a research range of 5-20 mg (5 mg as a conservative start, 20 mg at the high end), taken as cyclic 10-20 day courses roughly 2-3 times per year rather than continuously. These figures are research references, not a validated clinical regimen.
- Peak
- Not established — no human pharmacokinetic study published
- Bioavailability
- Not measured in humans
No measured human onset window exists. The 10-20 day cyclic course is a convention of the bioregulator literature rather than a time-to-effect finding, and no published human data supports a specific timeline.
Within the bioregulator literature it is discussed alongside the other tissue-directed Khavinson peptides — Vesugen (vascular), Livagen (liver), Testagen (reproductive tissue) — which are conventionally run as separate short courses rather than stacked together. There is no published evidence base for combining Cardiogen with anything.
Log every dose, count every vial, and verify your batches — free in the goodtides app.
This page is educational reference material about compounds studied in research settings. It is not medical advice, and nothing here is a recommendation to buy, possess, or use any compound. Research findings described are from published literature; individual compounds may not be approved for human use. Talk to a licensed clinician about anything that affects your health.